Lawsuits allege Taxotere (docetaxel) chemotherapy caused permanent hair loss — and separate claims allege it damaged tear ducts causing chronic tearing — risks patients say were never adequately disclosed.
Taxotere (docetaxel) is a chemotherapy drug widely used for breast, lung, and prostate cancers. While temporary hair loss is expected with chemotherapy, lawsuits allege Taxotere caused permanent alopecia — hair that never regrew — at rates far higher than patients were told.
A second wave of claims alleges Taxotere caused canalicular stenosis — scarring and blockage of the tear ducts — producing chronic excessive tearing (epiphora) and requiring surgical intervention. Plaintiffs allege the manufacturer knew of this complication but failed to warn oncologists in time to prevent it.
Federal claims were consolidated in MDL 2740 (hair loss) and MDL 3023 (tear-duct injuries) in the Eastern District of Louisiana. Much of the hair-loss litigation has resolved; tear-duct claims continue.
The hair-loss MDL (2740) has substantially resolved through settlements and dispositions. Tear-duct claims in MDL 3023 remain active — new claims continue to be evaluated for qualifying injuries.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Taxotere campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Taxotere Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.